title: Cyclooxygenase inhibitors reduce biofilm formation and yeast-hypha conversion of fluconazole resistant Candida albicans.
abstract: The incidence of fluconazole-resistant Candida albicans has been increasing worldwide. Both biofilm and fungal morphogenesis are main virulence factors of C. albicans cells. Extracellular fungal prostaglandins are synthesized during biofilm adhesion and development and through yeast-hypha conversion. Hence, we targeted prostaglandin synthesis with various cyclooxygenase (COX) inhibitors (aspirin, diclofenac, ketoprofen, tenoxicam, and ketorolac) and assessed their effect on fungal adhesion, biofilm formation, and yeast-hypha conversion in clinical isolates of Fluconazole resistant C. albicans. Significant reduction in fungal adhesion and detachment of mature biofilm was attained down to 1 mM concentrations of anti-inflammatory agents. Microscopical examination of fungal cells in the presence of the tested drugs showed significant reduction of germ tube formation. Therefore, COX inhibitors have a significant effect on reduction of Candida adhesion and biofilm development in correlation with fungal morphogenesis. Moreover, inhibition of C. albicans by COX inhibitors gave synergistic activity with fluconazole suggesting that combination therapeutic strategies may be fruitful for management of infection of Fluconazole resistant C. albicans.
authors.affiliation: Microbiology Department, Faculty of Pharmacy, Mansoura University, Mansoura, Dakahlia, 35516, Egypt.
authors.forename: E
authors.initials: E
authors.lastname: Abdelmegeed
authors.forename: Mona Ibrahim
authors.initials: MI
authors.lastname: Shaaban
mesh_terms: D000935:Antifungal Agents / Q000378:metabolism; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D002176:Candida albicans / Q000187:drug effects* / Q000502:physiology; D002448:Cell Adhesion / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000378:metabolism*; D015725:Fluconazole / Q000378:metabolism; D025301:Hyphae / Q000187:drug effects* / Q000254:growth & development
chemical_list: D000935:Antifungal Agents; D016861:Cyclooxygenase Inhibitors; D015725:Fluconazole
references.citation: J Antimicrob Chemother. 2009 Mar;63(3):473-9
references.pmid: 19098294
references.citation: Eur J Clin Microbiol Infect Dis. 1989 Jun;8(6):564-7
references.pmid: 2504601
references.citation: Infect Immun. 2007 Jul;75(7):3498-505
references.pmid: 17470538
references.citation: Clin Infect Dis. 2009 Mar 1;48(5):503-35
references.pmid: 19191635
references.citation: Infect Immun. 2001 May;69(5):2957-63
references.pmid: 11292712
references.citation: Eukaryot Cell. 2005 Apr;4(4):633-8
references.pmid: 15821123
references.citation: J Clin Microbiol. 2000 Dec;38(12):4626-8
references.pmid: 11101607
references.citation: Antimicrob Agents Chemother. 1995 Dec;39(12):2610-4
references.pmid: 8592988
references.citation: Curr Opin Microbiol. 2004 Aug;7(4):350-7
references.pmid: 15358253
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3411-3
references.pmid: 18573927
references.citation: J Infect Dis. 2012 Dec 1;206(11):1790-7
references.pmid: 22984120
references.citation: Infect Immun. 2003 Aug;71(8):4333-40
references.pmid: 12874310
references.citation: Folia Microbiol (Praha). 2011 Jul;56(4):349-52
references.pmid: 21713569
references.citation: Diagn Microbiol Infect Dis. 2002 May;43(1):85-6
references.pmid: 12052633
references.citation: Antimicrob Agents Chemother. 1995 Sep;39(9):2128-31
references.pmid: 8540729
references.citation: Infect Immun. 2002 Jan;70(1):400-2
references.pmid: 11748207
references.citation: Antimicrob Agents Chemother. 2004 Jan;48(1):41-7
references.pmid: 14693516
references.citation: Clin Microbiol Rev. 2003 Jul;16(3):517-33
references.pmid: 12857780
references.citation: Future Microbiol. 2006 Aug;1(2):209-18
references.pmid: 17661666
references.citation: Clin Microbiol Rev. 2007 Jan;20(1):133-63
references.pmid: 17223626
references.citation: Antimicrob Agents Chemother. 2012 Jun;56(6):3250-60
references.pmid: 22391539
references.citation: Trends Microbiol. 2001 Jul;9(7):327-35
references.pmid: 11435107
references.citation: J Microbiol Methods. 2000 Apr;40(2):175-9
references.pmid: 10699673
references.citation: J Antimicrob Chemother. 2002 Feb;49(2):345-51
references.pmid: 11815578
references.citation: Biochim Biophys Acta. 2000 Jul 19;1486(2-3):299-311
references.pmid: 10903481
references.citation: Int J Antimicrob Agents. 2006 Mar;27(3):196-200
references.pmid: 16459057
references.citation: J Med Microbiol. 1999 Jul;48(7):671-679
references.pmid: 10403418
references.citation: Microb Pathog. 2010 Mar-Apr;48(3-4):110-5
references.pmid: 20026399
references.citation: Crit Rev Oral Biol Med. 1999;10(3):359-83
references.pmid: 10759414
references.citation: Annu Rev Microbiol. 2007;61:529-53
references.pmid: 17506678
references.citation: Med Mycol. 2007 Jun;45(4):321-46
references.pmid: 17510856
references.citation: J Clin Microbiol. 2001 Sep;39(9):3234-40
references.pmid: 11526156
references.citation: J Med Microbiol. 2005 Nov;54(Pt 11):1001-1005
references.pmid: 16192429
references.citation: Clin Microbiol Rev. 2004 Apr;17(2):255-67
references.pmid: 15084500
references.citation: J Med Microbiol. 2000 Sep;49(9):831-840
references.pmid: 10966233
references.citation: Braz J Microbiol. 2010 Apr;41(2):286-94
references.pmid: 24031493
references.citation: Curr Opin Microbiol. 2006 Dec;9(6):588-94
references.pmid: 17055772
references.citation: Naturwissenschaften. 2000 May;87(5):236-40
references.pmid: 10883441
references.citation: FEMS Microbiol Rev. 2012 Mar;36(2):288-305
references.pmid: 21569057
references.citation: FEMS Microbiol Lett. 2001 Apr 20;198(1):37-43
references.pmid: 11325551
references.citation: Trends Microbiol. 2003 Jan;11(1):30-6
references.pmid: 12526852